SPRO News and Press, Spero Therapeutics Inc. From 11/01/23

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resis...

2023-11-01 08:36:50 ET More on Spero Therapeutics Spero Therapeutics, Inc. (SPRO) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Spero Therapeutics For further details see: Spero Therapeutics appoints Esther Rajavelu as CFO

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (M...

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resi...

BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of...

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resi...

2023-08-10 22:07:02 ET Spero Therapeutics, Inc. (SPRO) Q2 2023 Earnings Conference Call August 10, 2023 16:30 ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - Chief ...

2023-08-10 16:19:42 ET Spero Therapeutics press release ( NASDAQ: SPRO ): Q2 GAAP EPS of -$0.23 beats by $0.11 . Revenue of $2.72M (+36.7% Y/Y) beats by $1.64M . Total revenues for the second quarter of 2023 were $2.7 million, compared with revenues of $2.0 mil...

SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Sath Shukla Became President and CEO, Effective August 1 Conference call and webcast at 4:30pm ET today CAMBRIDGE...

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MD...